Clearance enables Phase 2 evaluation of NEO212, the Company’s oral perillyl alcohol-temozolomide conjugate, in the United ...

Dynamic clinical pathways are essential to keep pace with rapid advancements in oncology treatments and FDA approvals. Inclusive participation and effective communication are vital for pathway ...

New high-value indication for Phase 3-ready asset with data intended to support clinical development and strategic partnering ...

Developed in collaboration with Korea's top clinical and hospital network, the integrated platform combines globally ...

Olaparib in Patients With Solid Tumors With ATM Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study High levels of DNA replication stress and defects in the ...

Ryan Haumschild, PharmD, MS, MBA, drives an expert discussion focused on challenges associated with clinical pathway utilization in treating patients with HCC. The panel discussion focused on the ...

Biotechnology, healthcare, and biomedical technologies clearly are at the top of senior government officials’ priority list.

Expanding the Multidisciplinary Team in Prediagnostic Care of Lung Cancer: How Else Can We Improve Time to Targeted Treatment in Metastatic Non–Small-Cell Lung Cancer? In the article that accompanies ...

There is a complex pathological relationship between diabetes and osteoporosis, two of the most common chronic diseases worldwide.

Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF), the clinical-stage biopharmaceutical company, has received positive feedback from the US Food and Drug Administration (FDA) in a ...

Despite their importance, a significant number of biomarker strategies fail because they are added too late, are not feasible in real clinical settings, or are poorly aligned with clinical endpoints.